Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Late clonal complications in severe aplastic anemia

A Tichelli1, A Gratwohl, C Nissen

  • 1Departement fur Innere Medizin, Universitätsspital, Basel, Switzerland.

Leukemia & Lymphoma
|January 1, 1994
PubMed
Summary

Bone marrow transplantation (BMT) is superior to antilymphocyte globulin (ALG) therapy for severe aplastic anemia (SAA), significantly reducing the risk of clonal complications like myelodysplastic syndrome (MDS) and paroxysmal nocturnal hemoglobinuria (PNH).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017
Same author

Latin America: the next region for haematopoietic transplant progress.

Bone marrow transplantation·2017
Same author

Alloreactivity: the Janus-face of hematopoietic stem cell transplantation.

Leukemia·2017
Same author

Latin America: the next region for haematopoietic transplant progress.

Bone marrow transplantation·2017
Same author

The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis.

Bone marrow transplantation·2016
Same author

Allogeneic Bone Marrow Transplantation in Chronic Lymphocytic Leukemia: 17 Cases. Report of the EBMT.

Leukemia & lymphoma·2016

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Severe aplastic anemia (SAA) is a life-threatening condition.
  • Treatment options include bone marrow transplantation (BMT) and antilymphocyte globulin (ALG) therapy.
  • Long-term outcomes and complication risks associated with these treatments require further investigation.

Purpose of the Study:

  • To compare the long-term efficacy and safety of BMT versus ALG therapy in patients with SAA.
  • To assess the incidence of clonal complications, including myelodysplastic syndrome (MDS) and paroxysmal nocturnal hemoglobinuria (PNH), following SAA treatment.
  • To identify risk factors associated with the development of clonal complications.

Main Methods:

  • Retrospective analysis of 170 SAA patients treated between 1976 and 1992.

Related Experiment Videos

  • Comparison of outcomes between 41 patients who underwent BMT and 129 patients treated with ALG.
  • Long-term follow-up to assess survival rates and the incidence of clonal complications.

    • Main Results:

    • Overall survival at 15 years was 54% +/- 4%.
    • Clonal complications, including MDS and PNH, occurred exclusively in the ALG group, with a cumulative risk of 42% +/- 13% at 15 years.
    • Patients treated with BMT had no incidence of MDS or PNH, unlike the ALG group (p < 0.001).
    • Development of clonal disease significantly impacted long-term prognosis, with survival rates of 81% for stable disease versus 36% for clonal evolution (p = 0.001).

    Conclusions:

    • BMT is a safer treatment for SAA than ALG therapy, as it significantly reduces the risk of developing MDS and PNH.
    • Treatment type is the most critical factor influencing the risk of clonal complications in SAA.
    • Morphological parameters at diagnosis and during follow-up may indicate an increased risk for clonal evolution.